Sanofi signed an agreement on 6 July to acquire intellectual property covering non-chimeric antigen receptor (CAR) use of a novel binding domain that targets GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D) from Eureka Therapeutics, Inc. and Memorial Sloan Kettering Cancer Center. Eureka and the center each gets an undisclosed upfront payment and can split up to $1bn development, regulatory and sales milestones plus potential sales royalties from Sanofi.
GPRC5D is seen as a target that might offer a promising pathway for treating MM, especially in relapsed patients, Sanofi...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?